Clinical trial
A Double-Blind, Placebo-Controlled Single Dose Escalating Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2151 in Healthy Male Subjects, Followed by an Open, Two-Period Crossover Study to Assess the Effect of Fed Conditions on the Safety, Tolerability and Pharmacokinetics of ASP2151
NCT02852876 is registered in ClinicalTrials.gov with Astellas Pharma Europe Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Placebo-Controlled Single Dose Escalating Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2151 in Healthy Male Subjects, Followed by an Open, Two-Period Crossover Study to Assess the Effect of Fed Conditions on the Safety, Tolerability and Pharmacokinetics of ASP2151
- Lead sponsor
- Astellas Pharma Europe Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2005
- Completion date
- December 31, 2005
- Enrollment
- 72 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.